FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. A group of inventions is described, including an oligonucleotide for treatment of tau-associated disease in an individual (variants), a composition for treatment of tau-associated disease in an individual containing the above oligonucleotide, and the use of the above oligonucleotide for treatment of tau-associated disease in an individual in need thereof. In one embodiment of the invention, a polynucleotide contains a sequence of nucleotide bases that is at least 90% identical to any of the sequences
G*G*T*T*G*ACATCGTCTGC*C*T*G*T* or
G*G*T*T*G*AmCATmCGTmCTGmC*mC*T*G*T*,
wherein nucleotides with * have the 2’-O-MOE modification and mC stands for 5-methylcytosine.
EFFECT: invention expands the arsenal of tools to treat tau-associated disease in an individual.
15 cl, 15 dwg, 17 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF TAU | 2014 |
|
RU2745324C2 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| COMBINED PURIFICATION AND MEASUREMENT OF DNA METHYLATION WITH COMBINED MEASUREMENT OF MUTATIONS AND/OR LEVELS OF mRNA EXPRESSION IN AUTOMATED REACTION CARTRIDGE | 2017 |
|
RU2780660C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES | 2016 |
|
RU2812491C2 |
| IMMUNOSTIMULATING OLIGONUCLEOTIDES | 2018 |
|
RU2795701C2 |
| MODIFIED OLIGONUCLEOTIDES AND METHODS OF THEIR USE | 2017 |
|
RU2802836C2 |
